Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Revenue: 2013-2025

Historic Revenue for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $11.6 million.

  • Coherus Oncology's Revenue rose 91.19% to $11.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.7 million, marking a year-over-year increase of 152.07%. This contributed to the annual value of $267.0 million for FY2024, which is 3.78% up from last year.
  • Coherus Oncology's Revenue amounted to $11.6 million in Q3 2025, which was up 12.84% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Revenue registered a high of $248.3 million during Q4 2024, and its lowest value of $2.3 million during Q1 2024.
  • For the 3-year period, Coherus Oncology's Revenue averaged around $50.3 million, with its median value being $11.6 million (2025).
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 92.88% in 2024, then skyrocketed by 229.25% in 2025.
  • Over the past 5 years, Coherus Oncology's Revenue (Quarterly) stood at $73.4 million in 2021, then crashed by 38.17% to $45.4 million in 2022, then soared by 101.81% to $91.5 million in 2023, then soared by 171.30% to $248.3 million in 2024, then skyrocketed by 91.19% to $11.6 million in 2025.
  • Its last three reported values are $11.6 million in Q3 2025, $10.3 million for Q2 2025, and $7.6 million during Q1 2025.